Evaluation of the HemoCue WBC DIFF in leukopenic patient samples.
Background: White blood cell (WBC) counts are used to monitor bone marrow function and to screen for infections. The HemoCue WBC DIFF Point‐Of‐Care (POC) instrument classifies WBCs through cell image recognition. To evaluate its suitability for monitoring cancer patients, we examined its performance...
| Publicado en: | International Journal of Laboratory Hematology Vol. 42; no. 3; pp. 256 - 263 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Jun2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143246716&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 143246716 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17515521 47EA jtl: International Journal of Laboratory Hematology issn: 17515521 maglogo: Y pubinfo: dt: Jun2020 vid: 42 iid: 3 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 143246716 143246716 145811314 143246716 10.1111/ijlh.13158 143246716 ppf: 256 ppct: 7 formats: tig: atl: Evaluation of the HemoCue WBC DIFF in leukopenic patient samples. aug: au: Kur, Dår K. Agersnap, Niels Holländer, Niels Henrik Pedersen, Ole B. Vesterager Friis‐Hansen, Lennart affil: Department of Clinical Biochemistry, North Zealand Hospital, University of Copenhagen, Hilleroed, Denmark sug: subj: Leukocyte Count Equipment and Supplies Blood Cell Count Leukopenia Erythrocyte Count Human Female Male Cancer Patients Neutrophils Lymphocytes Regression Neutropenia Descriptive Statistics Correlation Coefficient Middle Age Aged Aged, 80 and Over Middle Aged: 45-64 years Aged: 65+ years Aged, 80 & over Female Male ab: Background: White blood cell (WBC) counts are used to monitor bone marrow function and to screen for infections. The HemoCue WBC DIFF Point‐Of‐Care (POC) instrument classifies WBCs through cell image recognition. To evaluate its suitability for monitoring cancer patients, we examined its performance in samples from patient with leukopenia and in samples containing nRBC. Methods: Sysmex samples with WBCs 0.05‐3.40 × 109/L were examined on the HemoCue WBC DIFF, and the correlations between the instruments were assessed by Deming regression for total WBC, neutrophils, and lymphocytes. The theoretical CV% (CVt), calculated from number of cells counted by the HemoCue WBC DIFF, was used to determine the statistical error of the WBC counts. The interference of nRBC was also evaluated. Results: The counting variation was primarily the source of statistical error in the lower counts with an imprecision between 3.8–9.2% for total WBC (0.56–2.29 ×109/L), 8.7–14.3% for neutrophils (0.36–1.33 ×109/L) and 9.8–15.1% for lymphocytes (0.35–0.89 ×109/L). The correlation coefficient was between 0.658 and 0.986—poorest for lymphocytes. The total WBC count on the HemoCue WBC DIFF was significantly increased in nRBC samples due to lymphocyte count overestimation, and not by other WBCs. Conclusions: The HemoCue WBC DIFF provided reliable and accurate counts of total WBC, neutrophil, and lymphocyte in leukopenic samples. Until POC instruments that can perform an accurate complete blood count are available, the HemoCue WBC DIFF can be used to assist physicians in making decisions in situations of postchemotherapy leukopenia and neutropenia. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|